Skip to main content
. 2017 Jul 10;8(35):59068–59085. doi: 10.18632/oncotarget.19146

Figure 3. Bio-CS nanoparticles hepatoma cell targeting in vitro and in vivo.

Figure 3

(A) Bio-CS nanoparticles hepatoma cell targeting in vitro. SMMC-7721 and LO2 cells were incubated with fluorescein isothiocyanate (FITC)-labeled GA-CTS for 4 h (n = 3). Fluorescence images were screened by confocal microscopy following nuclear staining with the fluorescent dye Hoechst 33258. (B) Dynamic image of Bio-GS nanoparticles in orthotopic transplantation liver cancer model. Following establishment of the orthotopic liver transplantation model at day 5, RBITC-CS, RBITC-Biotin and RBITC-Bio-CS nanoparticles were labeled by isothiocyanate Luo Danming B and were injected via the tail vein. The dynamic distributions in the mouse body were observed by an in vivo imaging system at 2, 4, 8, 12 and 24 h (n=3). (a): Image of orthotopic transplantation liver cancer model by the in vivo imaging system for each group at the different time points. (b): Histogram of the fluorescence photon number in liver cancer and liver tissues at the time point of 24 h. The data were analyzed by ANOVA test. aP<0.01, compared with CS; bP<0.01, compared with Biotin. (c): Histogram of C/L ratio in the liver at the time point of 24 h. The data were analyzed by ANOVA test. aP<0.01, compared with CS; bP<0.01, compared with Biotin. Bio-CS, biotinylated chitosan; SMMC-7721, human hepatocellular carcinoma cells; LO2, normal liver cells; FITC, fluorothioisocyanate; RBITC, Rhodamine B isothiocyanate; ANOVA, analysis of variance.